帕金森病患者脑室内注射胶质细胞源性神经营养因子后的临床病理结果

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.

作者信息

Kordower J H, Palfi S, Chen E Y, Ma S Y, Sendera T, Cochran E J, Cochran E J, Mufson E J, Penn R, Goetz C G, Comella C D

机构信息

Department of Neurological Sciences, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA.

出版信息

Ann Neurol. 1999 Sep;46(3):419-24. doi: 10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q.

DOI:10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q

PMID:10482276

Abstract

As part of a safety and tolerability study, a 65-year-old man with Parkinson's disease (PD) received monthly intracerebroventricular injections of glial-derived neurotrophic factor (GDNF). His parkinsonism continued to worsen following intracerebroventricular GDNF treatment. Side effects included nausea, loss of appetite, tingling, L'hermitte's sign, intermittent hallucinations, depression, and inappropriate sexual conduct. There was no evidence of significant regeneration of nigrostriatal neurons or intraparenchymal diffusion of the intracerebroventricular GDNF to relevant brain regions. Alternative GDNF delivery systems should be explored.

摘要

作为一项安全性和耐受性研究的一部分，一名65岁的帕金森病（PD）男性患者每月接受脑室内注射胶质细胞源性神经营养因子（GDNF）。在脑室内给予GDNF治疗后，他的帕金森症状持续恶化。副作用包括恶心、食欲不振、刺痛、莱尔米特征、间歇性幻觉、抑郁和不当性行为。没有证据表明黑质纹状体神经元有明显再生，也没有证据表明脑室内的GDNF在脑实质内扩散到相关脑区。应探索GDNF的替代递送系统。